What is the protocol for discontinuing an intravenous (IV) insulin infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Discontinuing an Intravenous Insulin Infusion Protocol

The protocol for discontinuing an intravenous (IV) insulin infusion involves administering subcutaneous insulin 1 to 2 hours before discontinuing the IV insulin, with the goal of minimizing rebound hyperglycemia while the subcutaneous insulin takes effect 1, 2, 3, 4, 1.

Key Steps in the Protocol

  • Subcutaneous Insulin Administration: Subcutaneous basal insulin should be given 1 to 2 hours before intravenous infusion is discontinued, with the aim of minimizing rebound hyperglycemia while the subcutaneous insulin action rises 2.
  • Dose Calculation: The dose of basal insulin is best calculated on the basis of the insulin infusion rate during the last 6 hours when stable glycemic goals were achieved 4.
  • Converting to Basal Insulin: Converting to basal insulin at 60% to 80% of the daily infusion dose has been shown to be effective 1.
  • Monitoring Blood Glucose Levels: Blood glucose levels should be closely monitored during this transition period, with target glucose ranges of 140-180 mg/dL.

Important Considerations

  • Preventing Hypoglycemia: Many episodes of hypoglycemia among inpatients are preventable, and a hypoglycemia prevention and management protocol should be adopted and implemented by each hospital or hospital system 4.
  • Correct Dosing: For patients transitioning to regimens with concentrated insulin (U-200, U-300, or U-500) in the inpatient setting, it is essential to ensure correct dosing by utilizing an individual pen and cartridge for each patient and by meticulous supervision of the dose administered 2, 4.

Transitioning to Subcutaneous Insulin

The transition protocol is associated with less morbidity and lower costs of care and is therefore recommended 1, 2, 3, 4, 1. A patient with type 1 or type 2 diabetes being transitioned to a subcutaneous regimen should receive a dose of subcutaneous basal insulin 1 to 2 hours before the intravenous infusion is discontinued.

From the Research

Discontinuing an Intravenous (IV) Insulin Infusion

There are no research papers to assist in answering this question, as the provided study 5 focuses on the initiation, titration, and switching of basal insulins in patients with type 2 diabetes, rather than the protocol for discontinuing an IV insulin infusion.

  • The study 5 discusses the management of basal insulins, including initiation, titration, and switching, but does not address IV insulin infusions.
  • The provided evidence does not include information on discontinuing IV insulin infusions, and therefore cannot be used to inform this process.

Related Questions

For a 21‑year‑old female weighing 79.3 kg with type 2 diabetes who takes methylprednisolone 1000 mg at 11 am together with NPH insulin (neutral protamine Hagedorn) 70 U (insulin‑to‑carbohydrate ratio 3 g/unit, insulin sensitivity factor 10 mg/dL per unit) and insulin glargine (Lantus) 20 U at 8 pm, with blood glucose readings of 383 mg/dL at 1 pm after eating 48 g carbohydrate, 344 mg/dL at 4 pm, 286 mg/dL at 6 pm, 272 mg/dL at 8 pm, and 221 mg/dL at 10 pm, what should the NPH insulin dose, insulin sensitivity factor, and insulin‑to‑carbohydrate ratio be adjusted to?
For a 25‑year‑old woman at 28 weeks gestation with type 2 diabetes, weight 114 kg, on insulin glargine (Lantus) 32 U daily, insulin‑to‑carbohydrate ratio 1 U:5 g, and insulin sensitivity factor 1 U:25 mg/dL, who ate 55 g carbohydrate at 6 pm and had blood glucose 183 mg/dL at 9 pm and fasting glucose 187 mg/dL, how should her insulin sensitivity factor, insulin‑to‑carbohydrate ratio, and basal insulin dose be adjusted?
I take 28 units of insulin glargine (basal insulin) once daily in the morning and my hemoglobin A1c is 7.1%; should I continue this dose or adjust it?
A patient taking 30 units of insulin glargine (Lantus) at bedtime has fasting glucose around 215 mg/dL; how much should the insulin dose be increased?
For a 114 kg pregnant woman with diabetes, what is the appropriate starting dose of insulin glargine (Lantus) and how should the basal dose be titrated, including total daily insulin requirement, insulin‑to‑carbohydrate ratio, and correction factor?
What is the efficacy of red yeast rice (RYR) compared to statins (HMG-CoA reductase inhibitors) in managing hyperlipidemia?
When to discontinue insulin drip in Hyperosmolar Hyperglycemic State (HHS) patients
Is long-term use of baclofen (GABA receptor agonist) safe?
What are the alternatives to Valtrex (Valacyclovir) for Herpes Simplex Virus (HSV)?
Does Tracheomalacia cause inspiratory or expiratory stridor?
What is the rationale for penicillin (antibiotic) prophylaxis in patients with Sickle Cell Disease (SCD) under 5 years of age?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.